Tenboron Ltd

Tenboron is a clinical stage biopharmaceutical company developing novel carriers for biologically targeted cancer radiotherapy called Boron Neutron Capture Therapy, BNCT. BNCT involves delivering boron-10 atoms selectively to cancer cells. When low energy neutron radiation is applied, the boron will react inside the cancer cells destroying them but sparing the surrounding healthy cells. Our proprietary boron carriers have been designed to deliver high amounts of boron to cancer cells maximizing the efficacy of BNCT. Our spearhead product, an antibody-boron conjugate TB0010 is currently in phase 1 clinical development for recurrent head and neck carcinomas.

This website uses cookies to ensure that we give you the best experience on our website.